State of Wisconsin Investment Board boosted its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 25.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,483,919 shares of the biopharmaceutical company’s stock after buying an additional 300,996 shares during the quarter. State of Wisconsin Investment Board owned 0.09% of Bristol-Myers Squibb worth $80,695,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. American National Bank raised its holdings in shares of Bristol-Myers Squibb by 36.0% in the 1st quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 508 shares in the last quarter. Welch Investments LLC raised its holdings in shares of Bristol-Myers Squibb by 3.9% in the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 79 shares in the last quarter. Crestwood Advisors Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $116,000. Blue Chip Partners Inc. raised its holdings in shares of Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in shares of Bristol-Myers Squibb by 2.8% in the 1st quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 60 shares in the last quarter. Institutional investors own 68.80% of the company’s stock.
Shares of Bristol-Myers Squibb Company (BMY) traded down 0.33% on Friday, reaching $62.48. 10,407,558 shares of the company’s stock traded hands. The stock has a market capitalization of $102.46 billion, a PE ratio of 22.82 and a beta of 1.18. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $63.47. The company has a 50 day moving average of $58.56 and a 200-day moving average of $55.95. Bristol-Myers Squibb also saw unusually large options trading activity on Thursday. Stock investors acquired 781 put options on the company. This is an increase of 117% compared to the typical daily volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.69 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.50%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by corporate insiders.
BMY has been the topic of a number of analyst reports. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price objective on the stock in a report on Monday, June 5th. BMO Capital Markets restated a “sell” rating and issued a $49.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 4th. Jefferies Group LLC restated a “buy” rating and issued a $64.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, June 5th. BidaskClub upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Deutsche Bank AG set a $55.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $62.66.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with our FREE daily email newsletter.